Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: October 22, 2025
Event: Special Meeting of Stockholders held via live webcast to vote on corporate governance proposals.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding stockholder voting results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
A quorum was established with 22,869,562 shares represented, approximately 46.61% of outstanding shares entitled to vote. Stockholders voted on two proposals:
- Proposal 1: Reverse Stock Split
- Outcome: Approved.
- Details: Authorization to effect a reverse stock split with a ratio between 1-for-5 and 1-for-30, at the Board's discretion.
- Votes: For: 18,333,570 | Against: 4,508,502 | Abstain: 27,490.
- Proposal 2: Adjournment
- Outcome: Approved.
- Details: Authorization to adjourn the meeting if necessary to solicit further proxies for Proposal 1.
- Votes: For: 18,869,741 | Against: 3,893,779 | Abstain: 106,042.
Guidance, Outlook, and Risks
The filing does not provide management commentary on financial guidance, future outlook, or specific risk factors. The primary operational implication is the Board's new authority to execute a reverse stock split within the approved range to potentially improve the trading price of the common stock.
Investor Verification Checklist
- Verify the exact reverse stock split ratio selected by the Board of Directors, as the filing only authorizes a range (1-for-5 to 1-for-30).
- Confirm the effective date of the reverse stock split and the record date for shareholders.
- Review the definitive proxy statement filed on September 9, 2025, for detailed rationale regarding the capital structure change.
- Monitor subsequent filings for the official implementation of the split and any resulting changes in share count.